Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | IKBKB | O14920 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317424 | 0.86 | GFER (1.00) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL3941869 | 0.86 | GFER (1.00) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL4586298 | 0.85 | GFER (0.76) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL6683286 | 0.85 | GFER (0.97) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL4972251 | 0.83 | GFER (0.94) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL6624747 | 0.81 | GFER (0.70) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL6683973 | 0.80 | GFER (0.68) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL31328298 | 0.78 | ALOX15 (0.64) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL31328323 | 0.78 | ALOX15 (0.64) | ALOX15MAPK1HSD17B10CASP1CASP7 | |
| SCHEMBL3110538 | 0.78 | ALOX15 (0.63) | ALOX15MAPK1HSD17B10CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024314-A1 | Methods of Treating Splenomegaly | TELIOS PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11642343-B2 | Methods of treating splenomegaly | TELIOS PHARMA, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | QUOGUE IP HOLDINGS LLC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220184069-A1 | METHODS OF TREATING SPLENOMEGALY | TELIOS PHARMA, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| CN-114423457-A | Method for treating splenomegaly | 泰利奥斯制药公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-110312713-A | Process for preparing tetrahydrocarbazole carboxamide compounds | 百时美施贵宝公司 | 2019-10-08 | — | — | CN | disclosed |
| US-8486990-B2 | SirT inhibitors that bind to NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | ALOX15 4154/4885MAPK1 239/4885HSD17B10 3992/4885 |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | BTK, BCL9L, BCL9 | ALOX15 2831/4885MAPK1 2415/4885HSD17B10 4234/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | ALOX15 4154/4885MAPK1 239/4885HSD17B10 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.